Abstract
Almost four decades ago, the characterization of the human immunodeficiency virus type 1 (HIV-1) genome with the participation of the Haseltine laboratory at Harvard Medical School ( Ratner et al., 1985) ushered in the antiretroviral era and established the framework for the genomic- and later multiple omics-based development of targeted antiviral drugs. Battles with pandemic HIV-1 taught us that multitargeted combination antiviral therapy is needed to control pathogens that rapidly adapt to selective pressures from the immune system, vaccines, and therapeutic monoclonal antibodies, such as pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains. The development of therapeutics active against all SARS-CoV-2 variants of concern and human coronaviruses could be expedited by taking approaches used for developing the inhibitors of HIV-1 integrase and capsid as well as hepatitis C virus, such as rationale-based drug design aided by generative artificial intelligence and chemistry. Here, we provide examples of cross-pollination between researches on HIV-1 and SARS-CoV-2 to identify potential SARS-CoV-2 therapeutic targets at various lifecycle stages.

This publication has 20 references indexed in Scilit: